<span item_type="fundamental" item_id="a543232e737a8e56ce1b447e000f7942" counter_id="ST/US/CPMD" env="prod"></span><span item_type="announcement" item_id="516804878539227521" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 335.32 K.</p><p>EPS: As of FY2025 Q1, the actual value is USD 0.</p><p></p><h3>Segment Revenue</h3><ul><li>Revenue for the three months ended March 31, 2025, was $335,319, compared to $25,839 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425005808/isdr_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Gross loss for the three months ended March 31, 2025, was - $502,607, compared to - $437,409 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425005808/isdr_10q.htm"></span></li><li>Loss from operations for the three months ended March 31, 2025, was - $667,700, compared to - $790,195 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425005808/isdr_10q.htm"></span></li><li>Net loss for the three months ended March 31, 2025, was - $690,594, compared to - $11,715,633 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425005808/isdr_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash used in operating activities for the three months ended March 31, 2025, was - $601,381, compared to - $548,829 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425005808/isdr_10q.htm"></span></li><li>Cash provided by financing activities for the three months ended March 31, 2025, was $600,433, compared to $560,272 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425005808/isdr_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The Company recognized revenue of $307,629 from the sale of cannabis products to Adjupharm GmbH, a pharmaceutical company based in Germany, during the three months ended March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425005808/isdr_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The Company plans to increase its growth capacity at the Cremona Facility to support sales of cannabis to European markets, focusing on Germany and Israel. This includes expanding operations from five to eleven growing rooms over the next one to two years and applying for EU-GMP certification to streamline the delivery process and reduce costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425005808/isdr_10q.htm"></span></li><li><strong>Non-Core Business</strong>: The Company entered into an agreement with LTB Management, LLC to build a sales network in the EU and access e-commerce technology for online cannabis sales. This agreement includes contingent consideration based on achieving $2,500,000 in annual revenue within 24 months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1081938/000165495425005808/isdr_10q.htm"></span></li></ul>

CannaPharmaRX, Inc. | 10-Q: FY2025 Q1 Revenue: USD 335.32 K